Top Pharmaceutical Companies
|
|
- Oscar Hodge
- 6 years ago
- Views:
Transcription
1 Parvez M Chowdhury (880) ; parvez@bracepl.com Top Pharmaceutical Companies Sector Rating: Outperform March 1, 2010 Square Pharma 2009A 2010E 2011E Revenue (MM BDT) 11, , ,098.9 Operating Income (MM BDT) 2, , ,537.1 Operating Margin 25% 24% 23% Net Income (MM BDT) 2, , ,456.9 Net Margin 18% 17% 16% 5-Year Revenue Growth (CAGR) 13% Capex (MM BDT) 2, , ,398.1 Debt/Equity 23% 20% 18% No. of Shares (MM) EPS (BDT) Dividend (BDT) Current Price (BDT) 3,554 Target Price (BDT) 4,000 Return (incl. Div yield) 14% Beximco Pharma 2008A 2009E 2010E Revenue (MM BDT) 4, , ,015.3 Operating Income (MM BDT) , ,635.3 Operating Margin 25% 26% 27% Net Income (MM BDT) Net Margin 14% 15% 16% 5-Year Revenue Growth (CAGR) 13% Capex (MM BDT) 1, Debt/Equity 34% 32% 29% No. of Shares (MM) EPS (BDT) Dividend (BDT) Current Price (BDT) 166 Target Price (BDT) 230 Return (incl. Div yield) 39% Renata Limited 2008A 2009E 2010E Revenue (MM BDT) 3, , ,005.0 Operating Income (MM BDT) ,151.2 Operating Margin 23% 23% 23% Net Income (MM BDT) Net Margin 14% 15% 15% 5-Year Revenue Growth (CAGR) 21% Capex (MM BDT) Debt/Equity 1% 0% 0% No. of Shares (MM) EPS (BDT) Dividend (BDT) Current Price (BDT) 11,310 Target Price (BDT) 13,000 Return (incl. Div yield) 15% ACI Limited 2008A 2009E 2010E Revenue (MM BDT) 10, , ,632.4 Operating Income (MM BDT) , ,239.2 Operating Margin 9% 9% 9% Net Income (MM BDT) Net Margin 9% 7% 3% 5-Year Revenue Growth (CAGR) 46% Capex (MM BDT) 1, , Debt/Equity 176% 155% 156% No. of Shares (MM) EPS (BDT) Dividend (BDT) Current Price (BDT) 509 Target Price (BDT) 675 Return (incl. Div yield) 35% Source BRAC EPL Research The pharmaceutical industry is one of the most developed among manufacturing industries in Bangladesh. Around 250 companies are operating in the market. The market size is estimated to be BDT billion, which grew by 16.83% in The market size in 2008 was BDT billion with a growth of 6.68%. One of the fastest growing sectors with an annual average growth rate of 14-16%, Bangladesh s pharmaceutical industry contributes to almost 1% of GDP. Local companies and MNCs together meet 95% of the country s drug demand but the local manufacturers dominate the industry; they enjoy approximately 87% of market share, while multinationals hold a 13% share. Another notable feature of this sector is the concentration of sales among a very small number of top companies. The top 15 players control around 73% of the market share. Given the country's lack of spending power, the pharmaceutical market remains tiny in comparison with the population size. Pharmaceutical spending is amongst the lowest in the world in per capita terms. Healthcare expenditures consist of only 3.4% of GDP. However, the increased awareness of healthcare and the government s increased expenditure in this sector is causing the demand to increase in this sector. In addition to the demand of therapeutic drugs, the demand for wellness drugs such as vitamins and minerals are increasing gradually and the future growth of the sector lies in it. In a recent market research by IMS, a US-based market research organization, Square Pharmaceuticals, Beximco Pharmaceuticals, Renata and ACI Limited secured top positions in the turnover leaders list. The estimates from IMS are not completely accurate and there is a margin of error of 10% in either direction. However, this is the only estimate with any accuracy for this sector. Square Pharma retained the top position with a local sales of BDT 10.70bn in Square s market share was a solid 19.48%. Beximco Pharma improved their sales from 2008 and 2007 with sales figure of BDT 4.2bn in 2009 (sales growth 27.15%). Beximco was at the No. 3 spot with a 7.72% market share. Renata had a sales growth of 25.63% in 2009 taking the seventh position. With a turnover of BDT 2.50bn, the company holds a market share of 4.54%. ACI Limited took the eighth place with 4.48% of market share. ACI s turnover stood at BDT 2.46bn. Table 1: Top Pharma Companies and Peers Company Current No. of Shares Price (BDT) (MM) Source BRAC EPL estimates for 2009 earnings Mcap (MM BDT) Free Float Avg Daily Trade (Last 30 Days) P/E P/B Square Pharmaceuticals 3, , % 52, x 4.4x Beximco Pharmaceuticals , % 1,032, x 2.6x Renata Limited 11, , % x 7.1x ACI Limited , % 216, x 2.9x GlaxoSmithKline , % 28, x 10.2x Reckitt Benckiser 1, , % 1, x 15.4x Average 37.2x 7.1x
2 Square Pharmaceuticals (Target price: BDT 4,000) Square Pharmaceuticals is the largest pharmaceuticals manufacturing company in the country. The company has consistently created value for its shareholders, with average Return on Equity (ROE) of over 20% in the last 7 years. While maintaining the profitability in its core pharma business, the company has created a number of other businesses in house in the past, and after profitable commercial operation of the businesses commenced, spun off such subsidiary businesses to monetize the investment. Square Pharmaceuticals has undertaken an expansion program to be completed in two phases. The first Phase will be completed in 2012 at a total cost of BDT 3.6b (we anticipate a 25% cost overrun for a final cost of 4.5b). This first phase is expected to almost double the current production capacity. The second phase starts in 2014, completing in 2017 for a total cost of 2.0b (including an estimated cost overrun of 25%). We expect the expansion programs contributing to revenue growth after Capital expenditure will be financed by internally generated cash as the company generates a handsome amount of cash each year Current debt to equity ratio is quite low at 23%; in the absence of any other major expansion plan, we do not anticipate assumption of any more debt. Some of the business units (e.g., Square Knit Farbics Ltd. and Square Cephalosporins Ltd.) are just starting to become profitable and more are on the right path (e.g., Square Hospitals Ltd.). Square will definitely benefit from this. We believe the company is still undervalued. We need to look a for the value of the company beyond 2013 as the major value addition to the company is going to take place after We believe the market has not yet identified the real value of the company. Based on 2013 estimated EPS of BDT 231, a price multiple of 22x (currently at 25.5x) and a discount rate of 13%, we arrive at a NPV of BDT 3,986. Target price BDT 4,000. Dividend yield 1.2%. Total return of 14%. Valuation Discounted FCF Operating cash 2,707 2,880 3,284 3,479 4,407 5,300 5,545 6,500 7,626 9,474 9,746 Capital expenditure -1,386-1,398-1,426-1, Increase/(reduction) in debt Free cashflow 1,321 1,482 1,858 2,028 3,558 4,431 4,689 5,654 7,226 9,074 9,346 Terminal value 153,264 NPV 55,914 Marketable Securities 3,628 NPV/Share 3,946 Discount rate 13% Perpetual growth 7% Square Pharma 2013 EPS 231 P/E 20.0x 22.0x 24.0x Price 4,627 5,090 5,552 P/B 2.0x 3.0x 4.0x Price
3 Square Pharma: Income Statement MM BDT E 2011E 2012E Net Turnover 8, , , , , ,287.3 Cost of Good sold 4, , , , , ,674.2 Gross profit 3, , , , , ,613.1 Selling & Distribution Expense , , , , ,208.6 Administrative Expense Depreciation Operating Profit 1, , , , , ,945.2 Other Income EBIT 2, , , , , ,315.7 Interest Expense Profit before WPPF 1, , , , , ,007.3 Provision for WPPF EBT 1, , , , , ,807.0 Tax ,046.9 PAT 1, , , , , ,760.0 Square Pharma: Balance Sheet MM BDT E 2011E 2012E Cash & Cash Equivalent , ,019.6 Short Term Loan to Associates 1, , Marketable Securities Adv, Deposit & Pre-Payment Accounts Receivable Inventories 2, , , , , ,645.4 Total Current Assets 4, , , , , ,452.9 Total Long Term Investment 2, , , , , ,110.9 Fixed Assets: PPE-Net of Depreciation 4, , , , , ,970.5 Capital Work In Progress , , , , ,200.8 Total Fixed Assets 5, , , , , ,171.3 Total Assets 12, , , , , ,735.1 Liabilities & Shareholders' Equity: Current Liabilities: Accounts Payable Liabilities for Expense Liabilities for Other Finance Short Term Bank Loan 2, , , , , ,712.2 Current Portion of LTD Total Current Liabilities: 3, , , , , ,376.6 Non Current Liabilities: Long Term Loan -Secured Deffered Tax Liability Minority Interest Total Non Current Liabilities , Total Liabilities 4, , , , , ,376.4 Shareholder's Equity: Share Capital , , , ,509.0 Share Premium 2, , , , , ,035.5 General Reserve Tax Holiday Reserve/Other 1, , , , , ,248.0 Retained Earnings 4, , , , , ,460.3 Total Shareholder's Equity 8, , , , , ,358.7 Total Liabilities & Equity 12, , , , , ,735.1
4 Beximco Pharmaceuticals Beximco Pharmaceuticals is one of the largest pharmaceutical companies in Bangladesh. The company has featured consistently in the top five manufacturers for the last decade. Beximco is widely regarded as one of the technological leaders among the local pharmaceutical companies in the country. The company utilizes state of the art technology. All new plants are equipped with cutting edge machineries. New facilities are coming online in 5 new plants. Two of them are already operational. The company maintains many good partnerships with established players such as Bayer AG of Germany and Upjohn Inc. of USA. The company has outperformed the industry in terms of sales during The pharmaceutical industry has grown around 15% on average annually and Beximco Pharma has matched that growth before We believe they will continue to emulate the performance of 2009 for the foreseeable future. Generally the company doubles their turnover in every three years. The company expects to generate BDT 700 million per month in Despite troubled political environment during 2007 and 2008, the company has successfully weathered the conditions and bounced back strongly under more favorable condition in New production lines become operational this year which will effectively double the capacity. The company has undertaken a hugely ambitious plan for foreign market. The management has targeted to have equal revenue from domestic sales and exports. That means they would have to achieve exponential growth in exports. Although this seems quite ambitious, there are signs that the management is on the right track to delivering what they promised. Target price BDT 230. Dividend yield 0.66%. Total return of 35%. Valuation Discounted FCF Operating Cash 915,856 1,133,017 1,523,378 1,914,524 2,344,024 2,693,460 3,017,023 Capital Expendture -333, , , , , , ,802 Change in Debt , ,554 1,265,977 1,741,722 2,171,222 2,520,658 2,844,221 Net Terminal Value 76,792,805 Terminal Value 80,349,238 Terminal Debt 3,556,433 Net Free Cash Flow 582, ,554 1,265,977 1,741,722 2,171,222 2,520,658 79,637,026 Discount Rate 13.0% NPV 39,322,708 Terminal Growth Rate 9% NPV/Share BEXIMCO Pharma Valuation EPS BVPS 2010 estimates Multiple 20.0x 2.5x Target price
5 Beximco Pharma: Income Statement Net Sales 3,702,317 3,597,025 4,010,167 5,012,709 6,015,251 7,218,301 Cost of goods Sold 1,809,860 1,813,233 1,855,687 2,406,100 2,887,320 3,248,235 Gross Profit 1,892,457 1,783,792 2,154,480 2,606,609 3,127,930 3,970,065 Administrative Expenses 150, , , , , ,549 Selling & Distribution Expenses 834, , , ,415 1,142,898 1,371,477 Depreciation Expense 161, , , , , ,601 Profit from Operation 746, , ,795 1,311,854 1,635,344 2,210,438 Other Income 56,201 19, ,532 15,038 18,046 Contribution to WPPF 26,162 19,984 35,706 37,595 45,114 54,137 Earning before Interest and Taxes (EBIT) 776, , ,775 1,286,791 1,605,267 2,174,347 Interest Expense 253, , , , , ,515 Earning Before Taxes (EBT) 523, , ,121 1,002,276 1,320,753 1,889,832 Income Tax (Current & Deffered) 52,585 46, , , , ,255 Profit After Tax (PAT) 470, , , , ,150 1,379,578 Beximco Pharma: Balance Sheet Assets: Current Assets: Cash & Cash Equivalent 581,099 85,699 73, ,450 1,639,117 2,657,386 Accounts Receivable 430, , , , , ,916 Spares and Supplies 182, , , , ,530 Loan, Advance & Deposit 591, , , , , ,509 Inventories 1,754,440 1,470,152 1,505,288 1,590,305 1,680,123 1,775,014 Total Current Assets 3,357,393 2,923,775 2,861,892 3,362,710 4,602,196 5,715,355 Fixed Assets: Property, Plant & Equipment 8,513,136 8,992,942 11,921,073 12,087,968 12,257,199 12,343,000 Investment in Shares 41,983 36,701 36,701 36,701 36,701 36,701 Total Fixed Assets 8,555,119 9,029,643 11,957,774 12,124,669 12,293,900 12,379,701 Total Assets: 11,912,512 11,953,419 14,819,665 15,487,379 16,896,096 18,095,056 Liabilities & Equities: Current Liabilities: Short Term Borrowing from Bank 1,302, ,582 1,461,666 1,461,666 1,461,666 1,461,666 CMLTD 712, , , , , ,166 Creditors & Other Payables 365, , , , , ,670 Accrued Expenses 117,937 60,053 81, , , ,143 Dividend payable 13,012 3,285 3,170 3,170 3,170 3,170 Income Tax Payable 16,276 41, , , , ,077 Total Current Liabilities 2,527,421 1,627,973 2,602,032 2,704,348 2,793,802 2,860,893 Non Current Liabilities: Long Term Borrowing-Secured 1,159,410 1,776,450 1,446,601 1,446,601 1,446,601 1,446,601 Deffered Liability-provision for gratuity 213, , , , , ,419 Deffered Tax Liability 62,403 51,352 46,411 46,411 46,411 46,411 Total Non-Current Liabilities 1,435,171 2,074,506 1,767,431 1,767,431 1,767,431 1,767,431 Shareholder's Equity: Share Cpaital 1,040,973 1,145,070 1,259,577 1,259,577 1,834,877 1,834,877 Share Premium 1,489,750 1,489,750 1,489,750 1,489,750 1,489,750 1,489,750 Issue price over face Value of GDR 1,689,637 1,689,637 1,689,637 1,689,637 1,689,637 1,689,637 Capital reserve 294, , , , , ,951 Tax-Holiday Reserve 394, ,355 1,711,175 1,711,175 1,711,175 1,711,175 Retained Earnings (including Tax holiday reserve from 2006E) 3,039,775 3,189,176 4,005,112 4,570,509 5,314,474 6,446,343 Total Equities 7,949,920 8,250,940 10,450,202 11,015,599 12,334,863 13,466,732 Total Liabilities & Equities 11,912,512 11,953,419 14,819,665 15,487,379 16,896,096 18,095,056
6 Renata Top Pharmaceutical Companies Renata is one of fastest growing pharmaceutical companies in Bangladesh. It is the seventh largest company in terms of local pharmaceutical sales. Successor of the business of Pfizer Bangladesh still enjoys distribution relationship with Pfizer. Renata is the market leader in agrochemical business. Strong growth history; in the last five years, revenue grew by a 23% CAGR whereas net profit grew by 31%. Even if gross profit margin remained the same, the company has consistently reduced its operating costs, thus improving the bottom line. The company achieved a return on equity of over 25% on average in the past five years seems to be on the same track. Renata boasts of the highest gross profit margin (almost 50%) among the local manufacturers. In 3Q09, Renata declared EPS of BDT posting a 43.55% bottom line growth QoQ; reduction of operating expenses improved bottom line. Renata has a Modest dividend payment; dividend yield in 2008 was about 1%. A high retention rate is justified as the company consistently makes huge capital expenditures, financed by internal cash. This state is supposed to continue in the near future. Manageable leverage; D/E is about 50%. The entire debt is short-term. Renata has good management, disciplined growth and low leverage, and appears to be an attractive company. Target price BDT 13,000. Dividend yield 0.55%. Total return 15%. Valuation Discounted FCF Operating Cash 490, , , , ,068, ,220, ,411,073.1 Capital Expendture -103, , , , , , ,426.7 Change in Debt -10, , , , , , ,078, ,259,646.4 Net Terminal Value 15,560,337.9 Terminal Value 15,560,337.9 Terminal Debt 0.0 Net Free Cash Flow 376, , , , , ,078, ,819,984.3 Discount Rate 13.5% NPV 9,438,570.8 Terminal Growth Rate 5.00% NPV/Share 6, Renata Valuation EPS BVPS 2011 estimates Multiple 20.0x 5.0x Target price
7 Renata: Income Statement Turnover 2, , , , , ,006.1 Cost of sales -1, , , , , ,003.0 Gross profit 1, , , , , ,003.0 Administrative, selling and distribution expenses , , ,621.6 Operating profit , ,381.4 Other income Gain on disposal of property, plant and equipment Other expenses , ,397.7 Interest on overdraft , ,307.1 Contribution to WPPF Profit before tax , ,246.5 Current tax Deferred tax Total tax Net profit after tax for the year Renata: Balance Sheet Current assets Inventories , , , ,801.8 Trade and other receivables Advance, deposits and prepayments Cash and cash equivalent ,195.8 Total current assets 1, , , , , ,628.3 Non-current assets Property, plant and equipment , , , ,165.9 Capital work-in-progress Investment Total non-current assets , , , , ,790.5 Total Assets 1, , , , , ,418.7 Current liabilities Bank overdraft Short term bank loans Dividend distribution tax Creditors for goods Accrued expenses Other payables Unclaimed dividend Provision for taxation Total current liabilities , , , ,481.1 Non-current liabilities Loans and borrowings Deferred liability-staff gratuity Deferred tax liability Total non-current liabilities Total liabilities , , , ,667.9 Equity attributable to equity holders of the group company Share capital Revaluation surplus Capital reserve Tax holiday reserve Proposed stock dividend Proposed cash dividend Retained earnings , , , , ,342.1 Total equity attributable to equity holders of the group company 1, , , , , ,750.8 Minority interest Total equity 1, , , , , ,750.8 Total equity and liabilities 1, , , , , ,418.7
8 ACI Limited Advanced Chemical Industries (ACI) Limited is one of the most recognized pharmaceutical companies in Bangladesh. ACI currently lies at eighth spot in the local market. The company has expanded its business beyond pharmaceuticals encompassing agrochemical, animal health, agro-machinery, consumer brands and retail chains. Since the company has been expanding its business horizon rather aggressively for the last few years, ACI has found itself in a cash crunch, which ultimately led the company to resort to a fair bit of leverage. However, ACI has recently issued a zero-coupon bond to improve their cash position. Despite cash constraint, ACI is one of the more consistent dividend paying companies in the local market. Although the core pharma segment and agribusiness segment are making respectable profits, consumer brands and other segments are not yet fully profitable. If and when these segments become profitable, the bottom line will see significant improvement. Despite its cash crunch, ACI remains one of the more attractive companies among the pharmaceutical companies. Target price BDT 675. Dividend yield 1.96%. Total return 35%. Valuation Discounted FCF Operating Cash 578,368,698 1,114,949,068 1,231,726,511 1,410,844,831 1,690,114,889 1,788,059,630 1,967,010,983 Capital Expendture -1,500,000, ,457, ,678, ,178, ,931, ,216, ,126,271 Change in Debt 315,090, ,599, ,000,000-1,070,816,761-1,200,000, ,000, ,000, ,540, ,091,401 64,048,280-60,150,210 65,183,313 1,136,843,627 1,287,884,712 Net Terminal Value 21,037,902,697 Terminal Value 23,396,572,260 Terminal Debt 2,358,669,563 Net freecashflow -606,540, ,091,401 64,048,280-60,150,210 65,183,313 1,136,843,627 22,325,787,409 Discount Rate 15.0% NPV 11,050,450,933 Terminal Growth Rate 9.00% NPV/Share ACI valuation EPS BVPS 2011 estimates Multiple 18.0x 3.0x Target price
9 ACI: Income Statement Revenue 4, , , , , ,139.4 Cost of sales 2, , , , , ,433.8 Gross profit 1, , , , , ,705.6 Admisnistrative expenses Distribution expenses Selling expenses , , , ,098.1 Operating profit , , ,639.1 Other income Result From opeating activities , , , ,709.7 Profit from sale of shares Share of Profit equity accounted investees EBIT , , , ,709.7 Financing cost , ,125.0 Provision for contribution to WPPF Profit before tax , ,068.8 Income tax expenses: Current tax expense Deferred tax income Profit after tax ACI: Balance Sheet Inventory 1, , , , , ,277.4 Trade debtors , , , ,294.8 Other debtors Advances, deposits and prepayments Advance income tax Inter-company receivable Cash and bank balances Total current assets 2, , , , , ,390.9 PPE at cost/revaluation 1, , , , , ,469.5 Accumulated depreciation , , ,835.1 PPE Net 1, , , , , ,634.4 Capital work-in-progress Intangible assets Investment Total non-current assets 1, , , , , ,142.1 Total assets 3, , , , , ,533.0 Bank overdraft , , , Short term bank loan 1, , , , , ,870.8 Long term bank loan- Current portion Trade creditors Other creditors , ,224.4 Inter company liability Current portion of lease obligation Provision for taxation Total current liabilities 2, , , , , ,799.1 Zero coupon bond 1, Long term bank loan Other liabilities Long term liabilities , ,425.7 Total liabilities 2, , , , , ,224.8 Share capital Share premium Capital reserve Special Reserve 0.1 Revaluation surplus Tax Holiday Reserve 34.5 Retained earnings , , , ,903.7 Total equity 1, , , , , ,000.2 Minority interest Total equity and liabilities 3, , , , , ,533.0
10 IMPORTANT DISCLOSURES Analyst Certification: Each research analyst and research associate who authored this document and whose name appears herein certifies that the recommendations and opinions expressed in the research report accurately reflect their personal views about any and all of the securities or issuers discussed therein that are within the coverage universe. Disclaimer: Estimates and projections herein are our own and are based on assumptions that we believe to be reasonable. Information presented herein, while obtained from sources we believe to be reliable, is not guaranteed either as to accuracy or completeness. Neither the information nor any opinion expressed herein constitutes a solicitation of the purchase or sale of any security. As it acts for public companies from time to time, BRAC-EPL may have a relationship with the above mentioned company(s). This report is intended for distribution in only those jurisdictions in which BRAC-EPL is registered and any distribution outside those jurisdictions is strictly prohibited. Compensation of Analysts: The compensation of research analysts is intended to reflect the value of the services they provide to the clients of BRAC-EPL. As with most other employees, the compensation of research analysts is impacted by the overall profitability of the firm, which may include revenues from corporate finance activities of the firm's Corporate Finance department. However, Research analysts' compensation is not directly related to specific corporate finance transaction. General Risk Factors: BRAC-EPL will conduct a comprehensive risk assessment for each company under coverage at the time of initiating research coverage and also revisit this assessment when subsequent update reports are published or material company events occur. Following are some general risks that can impact future operational and financial performance: (1) Industry fundamentals with respect to customer demand or product / service pricing could change expected revenues and earnings; (2) Issues relating to major competitors or market shares or new product expectations could change investor attitudes; (3) Unforeseen developments with respect to the management, financial condition or accounting policies alter the prospective valuation; or (4) Interest rates, currency or major segments of the economy could alter investor confidence and investment prospects.
Bata Shoe Bangladesh. Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods Rating: OUTPERFORM February 15, 2010
Price, BDT Turnover, MM Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com Bata Shoe Bangladesh DSE: Bloomberg: BATASHOE BATASH:BD Company Summary 52-week Price Range BDT
More informationDhaka Electric Supply Company (DESCO)
Thousands Aminul Haque, CFA (880) 171 417 8460; amin@eplbangladesh.com Dhaka Electric Supply Company (DESCO) November 2009 Recommendation: BUY Target Price: BDT 1,700 Company Summary 52-week Price Range
More informationParvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods
Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com British American Tobacco Bangladesh DSE: BATBC; Bloomberg: BATBC:BD Rating: OUTPERFORM January 20, 2010 Company Summary
More informationTitas Gas Transmission and Distribution Company Limited Fair Value Estimate (Dec 14) : BDT 111 per share Sector : Fuel and Power; Rating: OUTPERFORM
Dec-11 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Sep-12 Sep-12 Nov-12 Dec-12 Jan-13 Jan-13 Feb-13 Apr-13 Apr-13 May-13 Jun-13 Jul-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Price, BDT Turnover,
More informationAdvanced Chemical Industries Limited
Half Yearly Report for the period of six months ended on 30 June 2015 Statement of financial position As at As at Note 30 June 2015 31 December 2014 Assets Property, plant and equipment 2 4,093,475 3,799,146
More informationIPO Note on Indo-Bangla Pharmaceuticals Limited
IPO Note on Indo-Bangla Pharmaceuticals Limited Key IPO Facts IPO Size (BDT mn) 200 IPO Size (Shares mn) 20 Public Offer Price Per Share (BDT) 10 Authorized Capital (BDT mn) 1,000 Pre-IPO Paid up Capital
More informationWipro. 4QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 287. Recommendation: Hold
Wipro 4QFY18 Result Update Still not of the woods, maintain Hold Sector: Technology CMP: ` 287 Recommendation: Hold Market statistics Current stock price (`) 287 Shares O/S (cr.) 452.3 Mcap (` cr) 129,927
More informationParvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods
Price BDT Volume Millions Parvez M Chowdhury Analyst: Pharmaceuticals and Consumer Goods parvez@bracepl.com Beximco Pharmaceuticals Limited December 27, 2010 Rating: OUTPERFORM Company Summary 52-week
More informationWipro. 3QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 328. Recommendation: Hold
Wipro 3QFY18 Result Update Still not of the woods, maintain Hold Sector: Technology CMP: ` 328 Recommendation: Hold Market statistics Current stock price (`) 328 Shares O/S (cr.) 452.3 Mcap (` cr) 148,571
More informationInterim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2016
Interim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2016 Beximco Pharmaceuticals Limited 1 Statement of Financial Position (Un-audited) September 30, 2016 Notes September 30, 2016
More informationFIDSON HEALTHCARE PLC.
FIDSON HEALTHCARE PLC. EQUITY NIGERIA HEALTHCARE GTI Securities Research Coverage Analyst: Morolake Bisi-Afolabi Lead Analyst: Chuks Anyanwu c.anyanwu@gti.com.ng DECEMBER 15 th, 2015 Recommendation: BUY
More informationInterim Financial Statements (Un-audited) For the Half Year Ended December 31, 2016
Interim Financial Statements (Un-audited) For the Half Year Ended December 31, 2016 Beximco Pharmaceuticals Limited Statement of Financial Position (Un-audited) As at December 31, 2016 ASSETS Notes As
More informationInterim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2017
Interim Financial Statements (Un-audited) 1 st Quarter Ended September 30, 2017 Beximco Pharmaceuticals Limited Statement of Financial Position (Un-audited) September 30, 2017 ASSETS Notes September 30,
More informationACME Laboratories Limited
City Bank Capital - IPO Notes ACME Laboratories Limited ACME Laboratories Limited Cut-off Price IPO Book Building: BDT 85.2 and Offer Price IPO Subscription: BDT 77.0 per share [with BDT 75.2 and BDT 66.0
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/ Apr/15 May/ Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/ Dec/15 Parnax Lab Limited CMP: 53.90 January 08, 2016 Stock Details BSE code 506128 BSE ID PARNAXLAB Face value ( ) 10 No of shares
More informationChina TCM (570 HK) Buy (maintained) Target price: HK$ H17 earnings beat, 2017 growth guidance reaffirmed; TP raised to HK$5.
Oct-14 Dec-14 Feb-15 Apr-15 Jun-15 Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Equity Research Healthcare China TCM (570 HK) Buy (maintained) Target price: HK$5.40
More informationWipro. 3QFY17 Result Update. Guidance subdued, maintain Hold. Sector: Technology CMP: ` 474. Recommendation: Hold
Wipro 3QFY17 Result Update Guidance subdued, maintain Hold Sector: Technology CMP: ` 474 Recommendation: Hold Market statistics Current stock price (`) 474 Shares O/S (cr.) 243.1 Mcap (` cr) 115,090 52W
More informationRallis India NEUTRAL. Performance Highlights CMP. `242 Target Price - 4QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart
Jan-12 Jul-12 Jan-13 Jul-13 Jan-14 Jul-14 Jan-15 Jul-15 Jan-16 Jul-16 Jan-17 4QFY2017 Result Update Agrichemical May 2, 2017 Rallis India Performance Highlights Y/E March (` cr) 4QFY2017 3QFY2017 % chg
More informationLafarge Surma Cement Ltd. March 4, 2010
Aminul Haque, CFA (880) 171 417 8460; amin@eplbangladesh.com Md. Ashfaque Alam (Research Associate) ashfaque@bracepl.com Lafarge Surma Cement Ltd. March 4, 2010 Rating: OUTPERFORM Target Price: BDT 575
More informationRajesh Exports (RJEX_IN) Earnings Update Report Consumer Discretionary: Gold Jewelry Manufacturer
Monday, February 4, 2019 www.evaluateresearch.com Target Price Rs. 900.00 Current Price Rs. 598.00 Upside Potential 50% Market Cap. Shares Outstanding Rs. 176,802 mn US$ 2.47 bn 295.3 mn Free Float (FF
More informationPerformance Indicators for 6 years
Performance Indicators for 6 years FINANCIAL POSITION Balance sheet (Rupees in Thousand) Other noncurrent assets Total assets 2,084,856 6,544 2,436,65 2,040,33 11,386 2,257,568 4,417,23 1,803,2 101,268
More informationCummins India Ltd Bloomberg Code: KKC IN
Company Update Margins Under Pressure; Domestic Recovery Underway Half-yearly revenue was flat; margins were under pressure: Cummins India revenue, EBITDA and PAT for H1FY17 reached to Rs.24,784mn, Rs.4,649mn
More informationRallis India NEUTRAL. Performance Highlights CMP. `237 Target Price - 1QFY2018 Result Update Agrichemical. Investment Period - 3-year price chart
Jan-12 Jul-12 Jan-13 Jul-13 Jan-14 Jul-14 Jan-15 Jul-15 Jan-16 Jul-16 Jan-17 1QFY2018 Result Update Agrichemical July 26, 2017 Rallis India Performance Highlights Y/E March (` cr) 1QFY2018 4QFY2017 % chg
More informationDaewoong Pharmaceutical (069620)
Earnings Review July 31, 2014 12M rating BUY (Maintain) 12M TP W85,000 from W85,000 Up/downside +44% Stock Data KOSPI (Jul 30, pt) 2,083 Stock price (Jul 30, KRW) 58,900 Market cap (USD mn) 666 Shares
More informationJAIN IRRIGATION 07/06/2016 SECTOR: OTHERS. Initiating Coverage: ACCUMULATE. Company Snapshot:
Company Snapshot: Established in 1986 Jain Irrigation is a transnational organization headquartered at Jalgaon, Maharashtra. The company employs over 5 associates and manufacture a number of products,
More informationAlembic BUY. Performance Highlights. Target Price. 1QFY2011 Result Update Pharmaceutical. Investment Period 12 months
1QFY2011 Result Update Pharmaceutical August 2, 2010 Alembic Performance Highlights Y/E March (Rs cr) 1QFY2011 4QFY2010 % chg (qoq) 1QFY2010 % chg (yoy) Net Sales 279 267 4.6 291 (4.0) Other Income 1 1
More informationP20_Practice Test Paper_Syl12_Dec13_Set 1
Financial Analysis & Business Valuation Group-A (Answer Question 1 and 2 which are compulsory and any two from the rest) Question 1 CRISIL Limited (December 2010) Taxes on income Tax expense comprises
More informationReason for the report: INITIATING COVERAGE
CSL Stockbrokers LTD NIGERIA Equity Research Rating: A268** BAGCO Nigeria Plc: NIGERIA Conglomerate Date: 30 Nov 2007. Opinion Rating: A268 Price Target: Offer Price: NGN4.03 NGN3.90 M. Cap @ offer price:
More informationBSE Ltd (BSE) -New Initiatives to drive growth
BSE Ltd (BSE) -New Initiatives to drive growth BSE Ltd (BSE) 18-06-2018 Recommendation : Buy Strong brand recognition CMP : Rs 862 Target : NA % Allocation : 5% Sector : MISC Sensex : 35634 NSE code :
More informationGeely Auto (175 HK) EPS (Rmb) Turnover (Rmb m) Net profit. Sources: Company data, GF Securities (Hong Kong)
Equity Research Auto Geely Auto (175 HK) Buy (maintained) Target price: HK$ 33.29 Chongjing Deng SFC CE No. BEY953 dengchongjing@gf.com.cn +86 2 8757 6482 GF Securities (Hong Kong) Brokerage Limited 29-3/F,
More informationCMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212
2QCY17 Result Update July 20, 2017 Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212 Well-placed in Power T&D Hi-tech Space; Order Book Remains Robust India s revenue rose by 6.0% YoY to Rs23.3bn
More informationITC. 1QFY18 Result Update Higher Excise duty impacts sales; healthy EBITDA margin. Sector: FMCG CMP: ` 289. Recommendation: BUY
ITC 1QFY18 Result Update Higher Excise duty impacts sales; healthy EBITDA margin Sector: FMCG CMP: ` 289 Recommendation: BUY Market statistics Current stock price (`) 289 Shares O/S (cr.) 1216.2 Mcap (`cr)
More informationWEEK 10 Analysis of Financial Statements
WEEK 10 Analysis of Financial Statements Learning Objectives 1. Organize a systematic financial statements analysis using common-size financial statements and ratio analysis. 2. Recognize the potential
More informationKey estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9,
: price: EPS: How does our one year outlook change? We retain our positive view on EIM on the back of expected improvement in volume and margin at Royal Enfield (RE) and expected revival in VECV on the
More informationInterim Financial Statements (Un-audited) For the Half Year Ended December 31, 2017
Interim Financial Statements (Un-audited) For the Half Year Ended December 31, 2017 Beximco Pharmaceuticals Limited Statement of Financial Position (Un-audited) December 31, 2017 Notes December 31, 2017
More informationCadila Healthcare ACCUMULATE. Performance Highlights. CMP 860 Target Price QFY2013 Result Update Pharmaceutical. Key financials (Consolidated)
2QFY2013 Result Update Pharmaceutical November 7, 2012 Cadila Healthcare Performance Highlights ACCUMULATE CMP 860 Target Price 926 Y/E March (` cr) 2QFY2013 1QFY2013 % chg (qoq) 2QFY2012 % chg (yoy) Investment
More informationLincoln Pharmaceuticals Limited
25 January 2016 CMP: Rs.219.5 Industry: Healthcare BSE Group/Index: B/ Promoters Patel family Year of incorporation 1995 Registered office Lincoln House, B/h Satyam Complex, Science City Road, Viilage
More informationRajesh Exports Bloomberg: RJEX_IN Consumer Discretionary: Gold Jewellery Manufacturer
Monday, February 15, 2016 www.evaluateresearch.com Target Price Rs. 915.00 Current Price Rs. 720.00 Upside Potential 25% Market Cap. Shares Outstanding Rs. 214,048mn $ 3.15bn 295mn Free Float (FF %) 77mn
More informationZain KSA restructuring ensures fresh start
Vol mn RSI10 Zain KSA ZAINKSA AB: Saudi Arabia US$5.41bn 48.3% US$142.1mn Market cap Free float Avg. daily volume Target price 15.90 9.68% over current Consensus price 16.10 11.0% over current Current
More informationRallis India NEUTRAL. Performance Highlights CMP. `215 Target Price - 3QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart
3QFY2017 Result Update Agrichemical January 25, 2017 Rallis India Performance Highlights Y/E March (` cr) 3QFY2017 2QFY2017 % chg (qoq) 3QFY2016 % chg (yoy) Net sales 326 540 (39.7) 306 6.5 Other income
More informationMahindra & Mahindra Ltd.
May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Feb-18 4QFY2018 Result Update Automobile May 30, 2018 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr) 4QFY18 4QFY17
More informationITC. Q1FY17 Result Update Healthy Operational Performance; Maintain BUY. Sector: FMCG CMP: ` 251. Recommendation: BUY
ITC Q1FY17 Result Update Healthy Operational Performance; Maintain BUY Sector: FMCG CMP: ` 251 Recommendation: BUY Market statistics Current stock price (`) 251 Shares O/S (cr.) 1207.1 Mcap (` cr) 302,495
More informationTech Mahindra. 1QFY18 Result Update. Steps in the right direction, compelling valuation. Sector: Technology CMP: ` 385. Recommendation: Buy
Tech Mahindra 1QFY18 Result Update Steps in the right direction, compelling valuation Sector: Technology CMP: ` 385 Recommendation: Buy Market statistics Current stock price (`) 385 Shares O/S (cr.) 97.5
More informationINTER CA NOVEMBER 2018
INTER CA NOVEMBER 2018 Sub: FINANCIAL MANAGEMENT Topics Estimation of Working Capital, Receivables Management, Accounting Ratio, Leverages, Capital Structure. Test Code N16 Branch: Multiple Date: (50 Marks)
More informationGCC EQUITY REPORT NEUTRAL RESEARCH. Almarai Company (2280.SE) Quarterly Update. CMP SAR Target SAR Potential Upside 8.
l RESEARCH GCC EQUITY REPORT Almarai Company (2280.SE) NEUTRAL CMP SAR 106.50 Target SAR 115.00 Potential Upside 8.0% MSCI GCC Index 425.24 Tadawul All Share Index 6,697.80 Key Stock Data Sector Dairy
More informationCompany Overview. FY15 and recent performance. Company declared dividend of INR1.0 per share for FY15. Table 1: Key financials
Comm. Trading & Distribution l SME Research Ricoh India Ltd. CMP: INR945.25 Stock data BSE code 517496 BSE ID RICOHQ Face value (INR) 10 No of shares (m) 39.8 Market cap (INRm) 37,590.9 3m avg. daily vol
More informationResults Review. 3QFY13: Downsizing its workforce. Technology Bloomberg Ticker: UNI MK Bursa Code: November 2013
Results Review (Member of Alliance Bank group) PP7766/03/2013 (032116) 8 November 2013 Analyst Toh Woo Kim wookim@alliancefg.com +603 2604 3917 12-month upside potential Previous target price 0.89 Revised
More informationCapacity expansion to drive growth and profitability
STOCK POINTER Swaraj Engines Ltd. BUY Target Price `656 CMP `41 FY14 PE 6.9x Index Details Sensex 17,853 Nifty 5,39 BSE 1 5,367 Industry Auto parts Scrip Details Mkt Cap (` cr) 59 BVPS (`) 161 O/s Shares
More informationYansab Better than expected results
YANSAB AB: Saudi Arabia US$6.91bn 39.8% US$23.37mn Market cap Free float Avg. daily volume RSI10 Vol th Target price n/a n/a Consensus price 56.00 21.5% over current Current price 46.10 as at 9/2/2011
More informationBRAC Bank Ltd DSE: BRACBANK Bloomberg: BRAC:BD
Price, BDT Turnover, BDT MM Analysts: Sajid Huq sajid.huq@bracepl.com Farjad Siddiqui farjad.siddiqui@bracepl.com DSE: BRACBANK Bloomberg: BRAC:BD Company Summary Ticker BRACBANK Sector Bank Date of Operation
More informationKIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold
Latin American Equity Research Mexico City, November 20, 2006 KIMBERLY CLARK DE MEXICO Re-Rating Completed; Downgrading to Hold Joaquín Ley* Mexico: Santander Banco Santander S.A. 5255) 5269-1921 jley@santander.com.mx
More informationCardinal Health, Inc. - Financial and Strategic SWOT Analysis Review
Publication Date: FEB 2013 7000 Cardinal Place Phone Revenue Dublin, OH Fax Net Profit 43017 Website Employees United States Exchange Industry Company Overview Cardinal Health, Inc. (Cardinal Health) is
More informationR.S. Software (India) Ltd. 11 th August, 2014 BUY
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY R.S. Software (India) Ltd. 11 th August, 2014 BUY CMP Rs.430.00 Target Price Rs.600.00 BSE Code 517447 NSE Code RSSOFTWARE Market Cap (Rs
More informationFinancials/Valu CY15 CY16 CY17E CY18E FY19E
14-Nov-17 INDUSTRY - Con. Staples BLOOMBERG - NEST IN BSE Code - 579 NSE Code - NESTLEIND NIFTY - 1225 Company Data CMP 7715 Target Price 845 Previous Target Price 75 Upside 1% 52wk Range H/L Mkt Capital
More informationHavells India. Q1FY18 Result Update Strong Sales growth; Margins decline. Sector: Consumer Durable CMP: ` 467. Recommendation: BUY
Havells India Q1FY18 Result Update Strong Sales growth; Margins decline Sector: Consumer Durable CMP: ` 467 Recommendation: BUY Market statistics Current stock price (`) 467 Shares O/S (cr.) 62.5 Mcap
More informationfinancial Analysis Annual Report
financial Analysis Annual Report 217 87 DuPont Analysis Increase in sales volume by 16% coupled with increasing price trend during the year resulted in higher sales and profits due to which EBIT margin
More informationMahindra & Mahindra Ltd.
Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 Apr-18 Jul-18 Oct-18 Jan-19 3QFY2019 Result Update Automobile February 15, 2019 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr)
More informationNarnolia Securities Ltd. RAJEEV ANAND 28-Jul-17
28-Jul-17 INDUSTRY - Con. Staples BSE Code - 579 NSE Code - NESTLEIND NIFTY - 121 Company Data CMP 6789 Target Price 75 Previous Target Price 792 Upside 1 52wk Range H/L Mkt Capital (Rs Cr) Av. Volume
More informationCentury Plyboards (I)
Leading branded plywood player Visit note - Not rated 19 June 2014 Institutional Equities Century Plyboard (CPBI), India s leading plywood manufacturer with the highest-selling plywood brand, expects housing
More informationColgate-Palmolive. Q3FY17 Result Update Steep decline in Sales; EBITDA margin contraction continues. Sector: FMCG CMP: ` 879. Recommendation: HOLD
Colgate-Palmolive Q3FY17 Result Update Steep decline in Sales; EBITDA margin contraction continues Sector: FMCG CMP: ` 879 Recommendation: HOLD Market Statistics Current stock price (`) 879 Shares O/S
More informationCompany Research. Asian Paints Ltd Domestic paints volumes disappoint. Investment Overview: Date:
Asian Paints Ltd Domestic paints volumes disappoint Date: 30.8.2012 Investment Overview: Asian Paints is India s largest paint company & Asia s third largest paint company, with a turnover of Rs 96322.40
More informationORION PHARMA LIMITED AND ITS SUBSIDIARIES FINANCIAL STATEMENTS (UNAUDITED) FOR THE PERIOD ENDED 31 MARCH 2018 (THIRD QUARTER)
AND ITS SUBSIDIARIES FINANCIAL STATEMENTS (UNAUDITED) FOR THE PERIOD ENDED 31 MARCH 2018 (THIRD QUARTER) AND ITS SUBSIDIARIES Consolidated Statement of Financial Position (Unaudited) As at 31 March, 2018
More informationNRB BEARINGS LTD CMP. 16 July 2018 INR 164. Target Price. Initiating Coverage (BUY) INR 200
16 July 2018 NRB BEARINGS LTD CMP INR 164 Initiating Coverage (BUY) Target Price INR 200 Stock Details Industry Industrial Machinery Bloomberg Code NRBBR:IN BSE Code 530367 Face Value (Rs.) 2.00 Market
More informationHavells India. Q3FY17 Result Update Positive surprise; Maintain Buy. Sector: Consumer Durable CMP: ` 376. Recommendation: BUY.
Havells India Q3FY17 Result Update Positive surprise; Maintain Buy Sector: Consumer Durable CMP: ` 376 Recommendation: BUY Market statistics Current stock price (`) 376 Shares O/S (cr.) 62.5 Mcap (` cr)
More informationMobily high growth phase continues
Vol mn RSI10 Etihad Etisalat Company EEC AB: Saudi Arabia US$11.15bn 55.3% US$10.10mn Market cap Free float Avg. daily volume Target price 70.03 17.2% over current Consensus price 71.21 19.2% over current
More informationRecommendation BUY Snapshot CMP (01/08/2011) Rs. 85 Target Rs. 129
Recommendation BUY Snapshot CMP (01/08/2011) Rs. 85 Target Rs. 129 Sector Banking Stock Details BSE Code NSE Code Bloomberg Code Market Cap (Rs. Crs) Free Float (%) 52 wk HI/Low Avg. volume BSE (Quarterly)
More informationSymphony Ltd. RESULT UPDATE 31st October 2017
. RESULT UPDATE 31st October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October 2017. CMP INR 1,465 Target INR 1,700 Potential
More informationMahindra & Mahindra Ltd.
Nov-15 Jan-16 Apr-16 Jul-16 Oct-16 Jan-17 Apr-17 Jul-17 Oct-17 Jan-18 Apr-18 Jul-18 Oct-18 2QFY2019 Result Update Automobile November 15, 2018 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr)
More informationFORTE OIL PLC. FORTE OIL PLC: emergence of a new energy giant? Recommendation: HOLD FORTE OIL PLC FULL YEAR 2014:
FORTE OIL PLC EQUITY NIGERIA OIL AND GAS Coverage Analyst: Korede Ologun o.ologun@gti.com.ng Lead Analyst: Chuks Anyanwu c.anyanwu@gti.com.ng 11 March 2015 FORTE OIL PLC Bloomberg Ticker: FO: NL NSE Symbol:
More informationGMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months
2QFY2019 Result Update Industrial Machinery October 26, 2018 GMM Pfaudler Limited Performance Update Standalone (` cr) Q2FY19 Q2FY18 % yoy Q1FY19 % qoq Net sales 99.2 93.2 29.8% 76.4 6.4% EBITDA 16.0 15.3
More informationBRAC BANK LTD (BRACBANK)
BDT : 980.00 Tk. 1,600 1,400 1,200 1,000 800 600 400 200 0 31-Jan-07 3-Mar-07 BRAC Bank Adjusted Price-Volume Graph Volume Price 3-Apr-07 3-May-07 3-Jun-07 3-Jul-07 3-Aug-07 Farzana Hoque farzana@lbsbd.com
More informationSuzlon Energy Ltd RESULT UPDATE 16th August, 2017
RESULT UPDATE 16 th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now
More informationCompany Research. Result Highlights: EBITDA margin improve substantially by 120bps y-o-y: Date:
Asian Paints Ltd posted strong revenue growth due to festive season. Date: 23.01.2013 Result Highlights: Top-line grows by 18.61% yoy: Asian paints recorded sales of Rs.30371.40 mn against corresponding
More informationAn LBSL / JKSB Research Publication
BDT : 1,298.25 1,800 1,600 1,400 1,200 1,000 800 600 400 200 0 Heidelberg Cement Adjusted Price-Volume Graph 3-Jan-07 3-Mar-07 3-May-07 3-Jul-07 3-Sep-07 3-Nov-07 3-Jan-08 3-Mar-08 3-May-08 3-Jul-08 Volume
More informationSaudi Ceramic Expansion plan key growth driver
RSI10 Construction and Materials Industrial SCERCO AB: Saudi Arabia Rating NEUTRAL Target price SAR116. 0 (4.5% upside) Current SAR111.3 price Key themes & implications Company is one of the leading ceramic
More informationadesso AG MAY 31, 2012
WGZ BANK AG RESEARCH MAY 31, 2012 p. 1 AG MAY 31, 2012 Recommendation: Buy Company data before: - as of - Sector IT Target price (EUR) 9.20 Market segment General Standard Share price (Xetra) (EUR) 6.70
More informationITC. Rating: Target price: EPS: Relative better visibility despite the smoke, Maintain BUY CMP. Target. Rating. Rs.389. Buy. Rs.
: price: EPS: Relative better visibility despite the smoke, Maintain BUY ITC reported revenues of Rs.~87.2bn (+13% y-o-y), operating profits of Rs.32.8bn (+15% y-o-y) and PAT of Rs.~23.8bn (+16% y-o-y).
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 734.45 Target Price 845.00 WELSPUN INDIA LIMITED Result Update (CONSOLIDATED): Q2 FY16 OCTOBER 24 th 2015 ISIN: INE192B01023 Index Details Stock Data Sector Textiles BSE Code 514162 Face Value
More informationFila Korea (081660) Widespread growth potential
Fila Korea (8166) BUY (Maintain), TP: W98, (Maintain) Stock price (Apr 26, KRW) 83,5 Yr to Sales OP EBT NP EPS % chg EBITDA P/E EV/EBITDA P/B ROE Market cap (USD mn) 697 Dec (W bn) (W bn) (W bn) (W bn)
More informationSuggested Answer_Syl2012_Jun2014_Paper_20 FINAL EXAMINATION
FINAL EXAMINATION GROUP IV (SYLLABUS 2012) SUGGESTED ANSWERS TO QUESTIONS JUNE 2014 Paper- 20 : FINANCIAL ANALYSIS & BUSINESS VALUATION Time Allowed : 3 Hours Full Marks : 100 The figures in the margin
More informationChina Renewable Energy Investment Ltd (987_HK)
Wednesday, March 21, 2018 www.evaluateresearch.com Target Price HK$ 0.50 Current Price HK$ 0.23 Upside Potential 117% Market Cap. Shares Outstanding HK$ 525 mn $ 66.90 mn 2,364.7 mn Free Float (FF %) 631.9
More informationThe Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE**
The Brazil, Russia, India & China Over-the-Counter Pharmaceuticals Market to 2025 **SAMPLE** Pharmaceutical, commercial and strategic developments in the Brazil, Russia, India & China Over-the- Counter
More informationCMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143
1QFY18 Result Update July 25, 2017 Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143 Limited DPD Impact; Upgrade to (NCL) has delivered a decent performance in 1QFY18. Surpassing volume growth,
More informationKey estimate revision. Year FY14 23,28,609 3,48,027 1,40, FY15E 25,74,029 3,94,133 1,69,
: price: EPS: How does our one year outlook change? We retain our positive stance on TTMT driven by continued strong performance at JLR on both revenues & margins and expected reduction in losses at standalone
More informationWipro. 1QFY17 Result Update. Disappointing outlook, margin decline negative, Hold. Sector: Technology CMP: ` 549. Recommendation: Hold
Wipro 1QFY17 Result Update Disappointing outlook, margin decline negative, Hold Sector: Technology CMP: ` 549 Recommendation: Hold Market statistics Current stock price (`) 549 Shares O/S (cr.) 247.1 Mcap
More informationTrident Ltd. Buy & Add on dips
Trident Ltd. Buy & Add on dips 33,351.8 38,689.6 37,553.3 36,656.6 46,944.2 18-Apr-17 18-May-17 18-Jun-17 18-Jul-17 18-Aug-17 18-Sep-17 18-Oct-17 18-Nov-17 18-Dec-17 18-Jan-18 18-Feb-18 18-Mar-18 Trident
More informationORION PHARMA LIMITED AND ITS SUBSIDIARIES FINANCIAL STATEMENTS (UNAUDITED) AS ON 3OTH SEPTEMBEER 2017 (1ST QUARTER)
ORION PHARMA LIMITED AND ITS SUBSIDIARIES FINANCIAL STATEMENTS (UNAUDITED) AS ON 3OTH SEPTEMBEER 2017 (1ST QUARTER) ORION PHARMA LIMITED AND ITS SUBSIDIARIES Consolidated Statement of Financial Position
More informationTrevi Finanziaria. First half confirms growth trend. 20 September 2006 Industrials Change in Estimates. Price: 6.65 Target price: 7.
20 September 2006 Industrials Change in Estimates Price: 6.65 Target price: 7.70 Outperform 8.00 7.50 7.00 6.50 6.00 18/9/06 2004 2005 2006E 2007E EPS Adj. ( ) 0.04 0.20 0.38 0.48 DPS ( ) 0.02 0.07 0.12
More information2014 E 2015 E 2016 E 2017 E
Equity Research 4 December 2014 Interpump Group Hydraulics M&A may power growth Rating BUY Target price EUR13 Interpump is up 25% since the beginning of the year, bolstered by strong interim results and
More informationRNS Number : 2501V Beximco Pharmaceuticals Ltd 27 January 2017
RNS Number : 2501V Beximco Pharmaceuticals Ltd 27 January 2017 BEXIMCO PHARMACEUTICALS LTD. 27 January, 2017 Half Year Results 2016-17 Beximco Pharmaceuticals Limited ("BPL" or "the Company"; AIM Symbol:
More informationCompany Overview. Financial Performance
Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 CMP: 31.25 December 24, 2015 Stock Details BSE code 523878 BSE ID TOTEX Face value ( ) 10 No of shares (m) 8.1 Market
More informationLecture 23. Tuesday Apr 27 th. Financial Leverage
Lecture 23. Tuesday Apr 27 th Financial Leverage Balance Sheet Assets Land*! & Buildings*! Equipment*!! Machinery*!! Inventories*!!! Accounts Receivable*!!! Cash*!!! Liabilities Debt Secured* Unsecured
More informationBUY. KDDL LTD Result Update (PARENT BASIS): Q1 FY16 SYNOPSIS. CMP Target Price AUGUST 22 nd 2015 ISIN: INE291D01011
BUY CMP 280.10 Target Price 322.00 KDDL LTD Result Update (PARENT BASIS): Q1 FY16 AUGUST 22 nd 2015 ISIN: INE291D01011 Index Details Stock Data Sector Other Apparels & Accessories BSE Code 532054 Face
More informationKey estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,
: price: EPS: How does our one year outlook change? We retain our negative stance on the stock. We expect s revenue to de-grow by 9% y-o-y on the back of muted execution (client side and clearance delays)
More informationMaruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart
Jul-15 Sep-15 Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 1QFY2019 Result Update Automobile July 27, 2018 Maruti Suzuki India Performance
More informationBUY SIMPLEX INFRASTRUCTURES LTD SYNOPSIS. CMP Target Price FEBRUARY 28 th Result Update (PARENT BASIS): Q3 FY15
BUY CMP 408.40 Target Price 460.00 SIMPLEX INFRASTRUCTURES LIMITED Result Update (PARENT BASIS): Q3 FY15 FEBRUARY 28 th 2015 ISIN: INE059B01024 Index Details Stock Data Sector Construction & Engineering
More informationThe Varhad Group. Prag Bosimi Synthetics Ltd. Company Overview. FY15 and recent performance CMP: INR5.56. Stock data. Stock performance (%)
Textiles l BSE Research Prag Bosimi Synthetics Ltd. CMP: INR5.56 Stock data BSE code 500192 BSE ID PRAGBOS Face value (INR) 10.0 No of shares (m) 74.4 Market cap (INRm) 413.6 3m avg. daily vol (No) 2,491.6
More informationHardick Bora
BSE Sensex S&P CNX 19,990 6,069 Bloomberg JOL IN Equity Shares (m) 159.3 M.Cap. (INR b)/(usd b) 26.0/0.5 52-Week Range (INR) 248/154 1,6,12 Rel. Perf. (%) -18/-28/-34 Financials & Valuation (INR b) Y/E
More informationMulti-Cap Portfolio. Small- Mid- Cap. Cap. Large- Cap.
Multi-Cap Portfolio Multi-Cap Portfolio in which we are invest in stocks across multiple across market capitalization. That is, portfolio comprises of large cap, midcap and small cap stocks. Multi cap
More informationAdvisory Desk. TVS Srichakra Ltd. BUY CMP. `355 Target Price `468. Investment rationale. Outlook and valuation. Investment Period 12 Months
Ltd. Ltd. (TVSSL), a part of TVS Group, is a leading manufacturer of two and three-wheeler tyres with a 25% market share. Two-wheeler demand growth (~16% yoy YTD) continues to be insulated from the current
More information